China gives FibroGen its first approval for roxadustat

After over a decade of development, FibroGen Inc. (NASDAQ:FGEN) said China's National Medical Products Administration (NMPA) approved an NDA for roxadustat to treat anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent.

Roxadustat is the first approved drug against hypoxia-inducible factor prolyl hydroxylase (HIF-PH; EGLN), according to BioCentury’s BCIQ database...